Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users

Epidemics

Volumn 1, Issue 1, 2009, Pages 47-57

  Hahn, Judith A ^a   Wylie, Dennis ^b   Dill, Jesse ^c   Sanchez, Maria S ^b   Lloyd Smith, James O ^d   Page Shafer, Kimberly ^a   Getz, Wayne M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Seralogix   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dynamic modeling; Hepatitis C virus; Hepatitis C virus vaccine; Injecting drug users

Indexed keywords

HEPATITIS C VACCINE;

ARTICLE; CONTROLLED STUDY; DYNAMICS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK BEHAVIOR; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER DISEASE; PRIORITY JOURNAL; RISK REDUCTION; STOCHASTIC MODEL; UNITED STATES; VACCINATION;

COMPUTER SIMULATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; PREVALENCE; SAN FRANCISCO; STOCHASTIC PROCESSES; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL HEPATITIS VACCINES;

EID: 63449089688     PISSN: 17554365     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.epidem.2008.10.002     Document Type: Article

References (52)

1. Alter M. Transmission of hepatitis C virus - route, dose, and titer. N. Engl. J. Med. 330 11 (1994) 744-750
2. Altice F.L., Bruce R.D., et al. Adherence to hepatitis B virus vaccination at syringe exchange sites. J Urban Health 82 1 (2005) 151-161
3. Amon J.J., Garfein R.S., et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin. Infect. Dis. 46 12 (2008) 1852-1858
4. Backmund M., Meyer K., et al. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin. Infect. Dis. 39 10 (2004) 1540-1543
5. Burt R.D., Hagan H., et al. Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk behaviors, and preventive measures among Seattle injection drug users aged 18-30 years, 1994-2004. J. Urban Health 84 3 (2007) 436-454
6. Busch M.P. Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients. Transfus. Clin. Biol. 8 3 (2001) 200-206
7. Campbell J.V., Garfein R.S., et al. Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug users. Drug Alcohol Depend. 91 Suppl. 1 (2007) S64-S72
8. Currie S.L., Ryan J.C., et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug Alcohol Depend. 93 1-2 (2008) 148-154
9. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin. Infect. Dis. 40 Suppl 5 (2005) S336-338
10. Dalgard O., Bjoro K., et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur. Addict. Res. 8 1 (2002) 45-49
11. De P., Roy E., et al. Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review. J. Viral. Hepat. (2008)
12. Des Jarlais D.C., Perlis T., et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. Aids 19 Suppl 3 (2005) S20-25
13. Desbois D., Vaghefi P., et al. Sensitivity of a rapid immuno-chromatographic test for hepatitis C antibodies detection. J. Clin. Virol. 41 2 (2008) 129-133
14. Esposito N., and Rossi C. A nested-epidemic model for the spread of hepatitis C among injecting drug users. Math. Biosci. 188 (2004) 29-45
15. Folgori A., Capone S., et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat. Med. 12 2 (2006) 190-197
16. Garfein R.S., Vlahov D., et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am. J. Public Health 86 5 (1996) 655-661
17. Garfein R.S., Golub E.T., et al. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. Aids 21 14 (2007) 1923-1932
18. GlaxoSmithKline, "Twinrix Prescribing Information." Retrieved 11/28/07, from http://us.gsk.com/products/assets/us_twinrix.pdf.
19. Glynn S.A., Wright D.J., et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion 45 6 (2005) 994-1002
20. Grebely J., Conway B., et al. Hepatitis C virus reinfection in injection drug users. Hepatology 44 5 (2006) 1139-1145
21. Hagan H., and Des Jarlais D.C. HIV and HCV infection among injecting drug users. Mt. Sinai. J. Med. 67 5-6 (2000) 423-428
22. Hagan H., Des Jarlais D.C., et al. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Int. J. Drug. Policy. 18 5 (2007) 341-351
23. Hahn J.A. Sex, drugs, and hepatitis C virus. J. Infect. Dis. 195 11 (2007) 1556-1559
24. Hahn J.A., Page-Shafer K., et al. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 34 1 (2001) 180-187
25. Hahn J.A., Page-Shafer K., et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J. Infect. Dis. 186 11 (2002) 1558-1564
26. Houghton M., and Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 436 7053 (2005) 961-966
27. Hutchinson S.J., Bird S.M., et al. Modelling the spread of hepatitis C virus infection among injecting drug users in Glasgow: implications for prevention. Int. J. Drug Policy 17 (2006) 211-221
28. Kapadia F., Latka M.H., et al. Design and feasibility of a randomized behavioral intervention to reduce distributive injection risk and improve health-care access among hepatitis C virus positive injection drug users: the Study To Reduce Intravenous Exposures (STRIVE). J. Urban Health 84 1 (2007) 99-115
29. Krahn M.D., John-Baptiste A., et al. Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada. Vaccine 23 13 (2005) 1549-1558
30. Kretzschmar M., and Wiessing L.G. Modelling the spread of HIV in social networks of injecting drug users. Aids 12 7 (1998) 801-811
31. Lauer G.M., and Chung R.T. Vaccine-induced T-cell responses against HCV: one step taken, more to follow. Gastroenterology 132 4 (2007) 1626-1628
32. Law M., Maruyama T., et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14 1 (2008) 25-27
33. Logvinoff C., Major M.E., et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc. Natl. Acad. Sci. U. S. A. 101 27 (2004) 10149-10154
34. Lorvick J., Kral A.H., et al. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am. J. Public Health 91 1 (2001) 46-47
35. Lum P.J., Hahn J.A., et al. Hepatitis B virus infection and immunization status in a new generation of injection drug users in San Francisco. J. Viral. Hepat. 15 3 (2008) 229-236
36. Lum P.J., Ochoa K.C., et al. Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: the UFO study. Am. J. Public Health 93 6 (2003) 919-923
37. Mathei C., Shkedy Z., et al. Evidence for a substantial role of sharing of injecting paraphernalia other than syringes/needles to the spread of hepatitis C among injecting drug users. J. Viral. Hepat. 13 8 (2006) 560-570
38. Mather D., and Crofts N. A computer model of the spread of hepatitis C virus among injecting drug users. Eur. J. Epidemiol. 15 1 (1999) 5-10
39. McGregor J., Marks P.J., et al. Factors influencing hepatitis B vaccine uptake in injecting drug users. J. Public Health Med. 25 2 (2003) 165-170
40. Mehta S.H., Cox A., et al. Protection against persistence of hepatitis C. Lancet 359 9316 (2002) 1478-1483
41. Micallef J.M., Kaldor J.M., et al. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J. Viral. Hepat. 13 1 (2006) 34-41
42. Micallef J.M., Macdonald V., et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J. Viral. Hepat. 14 6 (2007) 413-418
43. Murray J.M., Law M.G., et al. The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. Int. J. Epidemiol. 32 5 (2003) 708-714
44. Operskalski E.A., Mosley J.W., et al. HCV viral load in anti-HCV-reactive donors and infectivity for their recipients. Transfusion 43 10 (2003) 1433-1441
45. Page-Shafer K., Pappalardo B.L., et al. Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and project HCV incidence rates. J. Clin. Microbiol. (2007)
46. Perz J.F., Armstrong G.L., et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. (2006)
47. Pollack H.A. Cost-effectiveness of harm reduction in preventing hepatitis C among injection drug users. Med. Decis. Making 21 5 (2001) 357-367
48. Thiede H., Hagan H., et al. Prevalence and correlates of indirect sharing practices among young adult injection drug users in five U.S. cities. Drug Alcohol Depend. (2007)
49. Tseng F.C., O'Brien R., T., et al. Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology 46 3 (2007) 666-671
50. van de Laar T.J., Langendam M.W., et al. Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, the Netherlands. J. Med. Virol. 77 4 (2005) 509-518
51. Vickerman P., Hickman M., et al. Modelling the impact on hepatitis C transmission of reducing syringe sharing: London case study. Int. J. Epidemiol. 36 2 (2007) 396-405
52. Volz E., and Meyers L.A. Susceptible-infected-recovered epidemics in dynamic contact networks. Proc. Biol. Sci. 274 1628 (2007) 2925-2933